SWOG clinical trial number
CTSU/A151804

ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS

Open
Phase
Abbreviated Title
ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OFIMMUNE-RELATED AE
Status Notes
This study is active in SWOG as of June 15, 2020.
Activated
06/15/2020

Research committees

Immunomolecular Therapeutics
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Leukemia
Lung Cancer
Lymphoma
Melanoma
Myeloma
Early Therapeutics & Rare Cancers

Eligibility Criteria Expand/Collapse

Please see eligibility criteria in protocol on www.CTSU.org

Publication Information Expand/Collapse

2020

ALLIANCE A151804: Establishment of a National Biorepository to Advance Studies of Immune-related Adverse Events

D Kozono;E Sharon;J Le-Rademacher;E Twohy;T Zemla;Y Wen;M Watson;E Dib;J Kirkwood;G Lyman;L Naidoo;A Nixon;E Mittendorf J Clin Oncol 38: 2020 (suppl; abstr TPS3154); American Society of Clinical Oncology 2020 Annual Meeting, poster

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase